Immunity, atherosclerosis and cardiovascular disease

Area of Science:

• Immunology
• Cardiovascular Medicine
• Pathology

Background:

• Atherosclerosis, a primary cause of cardiovascular disease (CVD), is characterized by chronic inflammation within lesions, driven by immune cells producing pro-inflammatory cytokines.
• Accumulation of dead cells and oxidized low-density lipoproteins (oxLDL) are hallmarks of atherosclerotic plaques, which are prone to rupture, the main cause of CVD.
• Oxidized LDL possesses pro-inflammatory and immune-stimulatory properties, induces cell death, and contains inflammatory phospholipids, notably phosphorylcholine (PC), an epitope targeted by atheroprotective antibodies.

Purpose of the Study:

• To review the potential causes of immune reactions and inflammation in atherosclerosis.
• To explore how inflammation can be therapeutically targeted for novel CVD treatments.

Main Methods:

• Literature review of existing studies on atherosclerosis pathogenesis and inflammation.
• Analysis of the role of oxidized LDL, immune cells, and inflammatory mediators in plaque development and rupture.
• Evaluation of potential therapeutic strategies targeting inflammatory pathways.

Main Results:

• Pro-inflammatory cytokines, chemokines, and lipid mediators are identified as direct causes of plaque rupture.
• Antibodies against phosphorylcholine (anti-PC) show potential atheroprotective effects, partly through anti-inflammatory mechanisms.
• While microbial involvement has been considered, direct evidence is limited, and antibiotic trials have been unsuccessful.

Conclusions:

• Clinical studies investigating anti-inflammatory and immune-modulatory treatments are crucial to confirm inflammation's causal role in atherosclerosis and CVD.
• Targeting inflammatory pathways presents a promising avenue for developing novel therapeutic interventions for cardiovascular disease.